Phio Pharmaceuticals Files 8-K
Ticker: PHIO · Form: 8-K · Filed: Jul 25, 2025 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Jul 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, financial-statements
TL;DR
Phio Pharma filed an 8-K on 7/25/25. Standard reporting.
AI Summary
Phio Pharmaceuticals Corp. filed an 8-K on July 25, 2025, reporting other events and financial statements. The company, formerly known as RXi Pharmaceuticals Corp., is incorporated in Delaware and headquartered in King of Prussia, PA.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain any material new information or significant events.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- RXi Pharmaceuticals Corp. (company) — Former company name
- July 25, 2025 (date) — Date of report
- King of Prussia, PA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of July 25, 2025.
What was Phio Pharmaceuticals Corp. formerly known as?
Phio Pharmaceuticals Corp. was formerly known as RXi Pharmaceuticals Corp.
In which state is Phio Pharmaceuticals Corp. incorporated?
Phio Pharmaceuticals Corp. is incorporated in Delaware.
What is the address of Phio Pharmaceuticals Corp.'s principal executive offices?
The address of Phio Pharmaceuticals Corp.'s principal executive offices is 411 Swedeland Road, Suite 23-1080, King of Prussia, PA 19406.
What is the telephone number for Phio Pharmaceuticals Corp.?
The telephone number for Phio Pharmaceuticals Corp. is (508) 767-3861.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 25, 2025 regarding Phio Pharmaceuticals Corp. (PHIO).